This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Epocrates To Report 2010 Fourth Quarter And Full-Year Financial Results And Host Conference Call On March 29, 2011

Epocrates, Inc. (NASDAQ:EPOC), a leading provider of mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry, will release its 2010 fourth quarter and full-year financial results and its financial guidance for 2011 on Tuesday, March 29, 2011, before regular market trading hours.

Epocrates will host a conference call and webcast the same day at 8:30 a.m. Eastern Time. Epocrates’ management will review its 2010 fourth quarter results and full-year operating results and future outlook, followed by a question and answer session.

To participate in Epocrates’ live conference call and webcast, please dial 877-398-9481 (if dialing from within the U.S.) or 760-298-5095 (if dialing from outside the U.S.) using conference code 47269531 or visit the Investor Relations section of Epocrates’ website at http://www.epocrates.com.

A replay of the conference call will be available approximately two hours after the completion of the conference call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing from outside the U.S.) using conference code 47269531. The replay will be available for one week on the above number. A webcast replay will also be archived on Epocrates’ website for approximately 12 months.

About Epocrates, Inc.

Epocrates is a leading provider of mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry. Epocrates’ active user network currently has more than one million healthcare professionals, including more than 45 percent of U.S. physicians. Most commonly used on mobile devices at the point of care, the company’s clinical products and services help healthcare professionals make more informed prescribing decisions, enhance patient safety and improve practice productivity. For more information about Epocrates, please visit www.epocrates.com/company.

Epocrates is a trademark of Epocrates, Inc., registered in the U.S. and other countries.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs